Glaxosmithkline
5 products tracked · names used in filings: Glaxosmithkline, Glaxosmithkline Llc, GlaxoSmithKline (Ireland) Limited
Upcoming milestones
No upcoming milestones listed.
Recent milestones
Tue 20 Oct 2026🇺🇸 FDA approval
FDA approves Hibsago (bepirovirsen), a new medicine
Glaxosmithkline Llc; NDA221276; New molecular entity, Priority review; injection · source
Wed 17 Jun 2026🇺🇸 FDA approval
FDA approves Utebzi (tebipenem pivoxil hydrobromide), a new medicine
Glaxosmithkline; NDA215960; New molecular entity, Priority review; tablet · source
Tue 16 Dec 2025🇺🇸 FDA approval
FDA approves Exdensur (depemokimab-ulaa), a new medicine
Glaxosmithkline Llc; BLA761458; New biologic; injection · source
Thu 23 Oct 2025🇺🇸 FDA approval
FDA approves Blenrep (belantamab mafodotin-blmf), a new medicine
Glaxosmithkline Llc; BLA761440; New biologic; injectable · source
Products
| Product | Status | Approved | |
|---|---|---|---|
| 🇺🇸 | Hibsago bepirovirsen | Approved | 2026-10-20 |
| 🇺🇸 | Utebzi tebipenem pivoxil hydrobromide | Approved | 2026-06-17 |
| 🇺🇸 | Exdensur depemokimab-ulaa | Approved | 2025-12-16 |
| 🇺🇸 | Blenrep belantamab mafodotin-blmf | Approved | 2025-10-23 |
| 🇪🇺 | Benlysta belimumab | Authorised | 2011-07-13 |
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.